Illumina (NASDAQ:ILMN) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of Illumina (NASDAQ:ILMN) in a report released on Saturday. The brokerage set a “buy” rating on the life sciences company’s stock.

ILMN has been the topic of a number of other research reports. Stephens reissued an “overweight” rating and set a $170.00 target price on shares of Illumina in a report on Tuesday, May 7th. Evercore ISI lowered their price target on Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 11th. Royal Bank of Canada restated an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a report on Tuesday, April 9th. Jefferies Financial Group assumed coverage on Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 price target on the stock. Finally, Barclays boosted their price objective on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Illumina has a consensus rating of “Hold” and a consensus price target of $158.14.

Illumina Stock Up 0.3 %

Shares of NASDAQ ILMN opened at $108.57 on Friday. The company’s 50 day moving average price is $112.71 and its 200-day moving average price is $127.51. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75. Illumina has a 52-week low of $89.00 and a 52-week high of $202.85. The company has a market capitalization of $17.30 billion, a P/E ratio of -13.32 and a beta of 1.20.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period last year, the business posted $0.08 EPS. Equities analysts forecast that Illumina will post 1.04 earnings per share for the current year.

Institutional Trading of Illumina

Several institutional investors and hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC grew its position in shares of Illumina by 2.9% during the 3rd quarter. Kestra Advisory Services LLC now owns 8,878 shares of the life sciences company’s stock worth $1,219,000 after buying an additional 252 shares in the last quarter. QRG Capital Management Inc. bought a new stake in shares of Illumina in the 3rd quarter valued at about $462,000. Envestnet Portfolio Solutions Inc. purchased a new stake in shares of Illumina in the 3rd quarter worth approximately $407,000. Aigen Investment Management LP bought a new position in shares of Illumina during the third quarter valued at approximately $226,000. Finally, LPL Financial LLC increased its holdings in Illumina by 133.7% during the third quarter. LPL Financial LLC now owns 99,315 shares of the life sciences company’s stock valued at $13,634,000 after buying an additional 56,819 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.